Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
نویسندگان
چکیده
AIM Treatment of chronic kidney disease (CKD) includes parenteral iron therapy, and these infusions can lead to iron overload. Secondary iron overload is typically treated with iron chelators, of which deferasirox is one of the most promising. However, it has not been studied in patients with CKD and iron overload. METHODS A pilot study was conducted to evaluate the pharmacokinetics and safety of deferasirox in eight haemodialysis-dependent patients, who were receiving intravenous iron for treatment of anaemia of CKD. Deferasirox was administered at two doses (10 mg/kg and 15 mg/kg), either acute (once daily for 2 days) or steady-state (once daily for 2 weeks). RESULTS A dose of 10 mg/kg in either protocol was not sufficient to achieve a plasma concentration in the therapeutic range (acute peak 14.1 and steady-state 22.8 μmol/L), while 15 mg/kg in either protocol maintained plasma concentration well above this range (acute peak 216 and steady-state 171 μmol/L). Plasma concentration observed at 15 mg/kg was well above that expected for this dose (40-50 μmol/L), although no adverse clinical events were observed. CONCLUSION This study highlights the need to profile drugs such as deferasirox in specific patient groups, such as those with CKD and iron overload.
منابع مشابه
Pharmacokinetics and Safety of Deferasirox in Subjects with Chronic Kidney Disease Undergoing Haemodialysis Running title: Deferasirox in chronic kidney disease
Aim: Treatment of chronic kidney disease (CKD) includes parenteral iron therapy, and these infusions can lead to iron overload. Secondary iron overload is typically treated with iron chelators, of which deferasirox is one of the most promising. However, it has not been studied in patients with CKD and iron overload. Methods: A pilot study was conducted to evaluate the pharmacokinetics and safet...
متن کاملErratum to Parasrampuria et al. "Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis" (Thromb Haemost 2015; 113: 719-727).
[This corrects the article DOI: 10.1160/TH14-06-0547.].
متن کاملPharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Edoxaban is an oral, direct, once-daily, factor Xa inhibitor developed for stroke prevention in patients with atrial fibrillation and for the treatment and secondary prevention of recurrent thromboembolism in patients with acute symptomatic venous thromboembolism. Among elderly patients who require anticoagulation therapies, some may have end-stage renal disease (ESRD). This open-label, phase 1...
متن کاملTherapeutic Effect of Deferasirox and Glycine on Chronic Cadmium Toxicosis in Rats
Objective: It has been shown that deferasirox can reduce blood and tissues lead content in animal models. In this study the effect of deferasirox alone or combined with glycine as an antioxidant was evaluated in chronic cadmium toxicosis in rat. Methods: Male wistar albino rats were exposed to 200 ppm cadmium in the drinking water for 3 weeks and treated thereafter with deferasirox (140 mg/kg),...
متن کاملTherapeutic Effect of Deferasirox and Glycine on Chronic Cadmium Toxicosis in Rats
Objective: It has been shown that deferasirox can reduce blood and tissues lead content in animal models. In this study the effect of deferasirox alone or combined with glycine as an antioxidant was evaluated in chronic cadmium toxicosis in rat. Methods: Male wistar albino rats were exposed to 200 ppm cadmium in the drinking water for 3 weeks and treated thereafter with deferasirox (140 mg/kg),...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Nephrology
دوره 18 3 شماره
صفحات -
تاریخ انتشار 2013